Initially, the alliance will develop treatment options for patients with two rare, life-threatening primary immunodeficiency diseases -- Wiskott-Aldrich Syndrome (WAS) and X-linked Agammaglobulinemia (XLA) [02-June-2020] SEATTLE and KING of PRUSSIA, Pa. , June 2, 2020 /PRNewswire/ -- Seattle Children’s Research Institute, one of the top pediatric research institutio
June 2, 2020
· 5 min read